Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) said on Monday that Alexion, AstraZeneca Rare Disease's Klygefa (gefurulimab) has been approved in both the US and the European Union for adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis (gMG).
The treatment is a dual-binding nanobody C5 inhibitor administered once weekly by subcutaneous autoinjector.
Both approvals were supported by results from the Phase III PREVAIL trial, in which Klygefa met its primary endpoint, demonstrating an improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 26 versus placebo (treatment difference: -1.6 [95% CI: -2.4, -0.8], p
BioArctic and Eisai report positive five-year data for Leqembi in early Alzheimer's disease
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
AstraZeneca rare disease unit secures US and EU approvals for Klygefa in myasthenia gravis
Genentech secures first FDA approval for primary membranous nephropathy treatment
Aelis Farma announces receipt of second positive safety recommendation for Down syndrome trial
Specialised Therapeutics' YONDELIS sarcoma therapy approved in Thailand
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Eisai launches subcutaneous Leqembi Pen in Japan for early Alzheimer's disease
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme
Shanton Pharma's SAP-001 receives EMA and FDA paediatric study waivers in hyperuricaemia